Belite Bio Aims for FDA Submission After Positive Stargardt Trial Results
Event summary
- Belite Bio completed a $402 million public offering, boosting its cash position to $352.9 million as of December 31, 2025.
- The company's Phase 3 DRAGON trial of tinlarebant for Stargardt disease met its primary endpoint, showing a 35.7% reduction in macular lesion growth.
- Belite Bio plans to submit a New Drug Application (NDA) for tinlarebant to the FDA in Q2 2026.
- The DRAGON II trial for Stargardt disease enrolled 72 subjects as of February 27, 2026, exceeding its target of 60.
The big picture
Belite Bio's positive Phase 3 trial results for tinlarebant position it as a potential first-in-class therapy for Stargardt disease, a condition with no approved treatments. The company's substantial fundraising and strong cash position suggest it is well-prepared for the next phase of regulatory and commercial execution. The success of tinlarebant could set a new benchmark for treatments targeting degenerative retinal diseases, including geographic atrophy.
What we're watching
- Regulatory Timeline
- Whether Belite Bio can maintain its Q2 2026 NDA submission timeline for tinlarebant, given the complexity of the FDA review process.
- Clinical Trial Success
- The pace at which the DRAGON II trial progresses and whether it replicates the positive results of the DRAGON trial.
- Financial Runway
- How Belite Bio allocates its $402 million in new funding to support both commercialization and further pipeline development.
Related topics